Aradigm Corporation
Description Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. Its lead development candidates include Pulmaquin (ARD-3150) and Lipoquin (ARD-3100), which completed Phase IIb clinical trials for the management of infections associated with the severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). Its products under development also comprise ARD-1100, a liposomal ciprofloxacin for the treatment of inhalation anthrax and other biodefense purposes; and ARD-1600, an inhaled nicotine product for smoking cessation. The company was founded in 1991 and is headquartered in Hayward, California. To view the detailed information, you need to SUBSCRIBE with us. |
 |